TAGCyx Biotechnologies, Inc. (Tokyo, Japan) has raised approximately 210 million JPY from UTokyo Innovation Platform Co., Ltd., SBI Group and Healthcare Innovation Co., Ltd.
TAGCyx is developing unique DNA aptamers called “Xenoligo®” for therapeutic purpose, using proprietary artificial nucleic acid base pair technology. Oligonucleotide aptamers are single strand DNA or RNA that bind to specific molecules due to its unique 3-D structure. Xenoligo® has features of high binding affinity to proteins by particular hydrophobic interaction of proprietary artificial bases and stabilization by proprietary Mini-hair pin technology, therefore it is possible to generate and develop Xenoligo® for therapeutic purpose.
Based on the platform technology of Xenoligo®, TAGCyx has concentrated management resources in the drug discovery business since 2016, and through multiple steps of financing, has entered into several collaboration agreements with pharmaceutical and healthcare companies. Achieving this funding, TAGCyx will accelerate the expansion and stage-up of development pipeline and contribute to healthcare.